Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Equity Average (2020 - 2025)

Apellis Pharmaceuticals has reported Equity Average over the past 6 years, most recently at $385.7 million for Q4 2025.

  • Quarterly results put Equity Average at $385.7 million for Q4 2025, up 65.64% from a year ago — trailing twelve months through Dec 2025 was $385.7 million (up 65.64% YoY), and the annual figure for FY2025 was $299.3 million, up 41.51%.
  • Equity Average for Q4 2025 was $385.7 million at Apellis Pharmaceuticals, up from $278.7 million in the prior quarter.
  • Over the last five years, Equity Average for APLS hit a ceiling of $398.3 million in Q2 2022 and a floor of -$99.4 million in Q3 2021.
  • Median Equity Average over the past 5 years was $244.7 million (2022), compared with a mean of $225.8 million.
  • Biggest five-year swings in Equity Average: tumbled 158.84% in 2021 and later surged 986.8% in 2022.
  • Apellis Pharmaceuticals' Equity Average stood at $70.7 million in 2021, then surged by 237.7% to $238.6 million in 2022, then dropped by 10.58% to $213.4 million in 2023, then increased by 9.11% to $232.8 million in 2024, then soared by 65.64% to $385.7 million in 2025.
  • The last three reported values for Equity Average were $385.7 million (Q4 2025), $278.7 million (Q3 2025), and $160.3 million (Q2 2025) per Business Quant data.